Annual Uterine Cancer Symposium

子宫内膜癌是美国最常见的妇科恶性肿瘤。资金 子宫内膜癌传统上落后于其他妇科肿瘤，如宫颈癌， 癌症和卵巢癌。因此，过去一直缺乏协调一致的基本和 致力于子宫内膜癌的转化研究工作。2003年，一群基础科学家和医生- 来自MD的科学家安德森癌症中心申请并获得了NCI资助的子宫内膜 癌症孢子。这组调查人员目前代表了联邦政府唯一集中的一组调查人员。 资助了美国的子宫内膜癌研究人员。创新，转化研究， 子宫内膜癌要向前发展，就必须汇集临床研究人员， 来自全国各地不同机构的实验室科学家。因此，我们建议 组织每年一次的子宫癌研讨会，目标如下：1）提供一个有意义的论坛， 讨论子宫内膜癌生物学的前沿发展; 2）吸引相关领域的专家（如 乳腺癌和内分泌学），以鼓励多学科的互动; 3）促进合作 基础科学家和临床研究者之间的合作，以开发更具创新性、高影响力的 子宫内膜癌的转化研究;和4）鼓励年轻，有才华的博士后研究员，临床 住院医师/研究员，以及助理教授级别的教师进入子宫内膜癌研究领域。 拟议的子宫内膜癌研讨会将每年在德克萨斯州休斯顿举行。我们 2002年在休斯敦成功举办了第一届子宫癌生物学研讨会， 2004年9月27日和28日举行的第二届研讨会的发言人名单。的议题 每年的子宫癌研讨会系列包括子宫内膜癌的激素机制，分子 侵袭性（2型）和非侵袭性（1型）子宫内膜癌之间的差异， 子宫内膜癌，高危人群的化学预防，子宫内膜增生/风险生物标志物， 子宫内膜癌的小鼠和细胞培养模型，以及正常子宫内膜癌中重要的遗传事件 发展对于每一个研讨会，临床主题和基础科学主题的混合物将提交给 ）促进高质量翻译研究的发展。

Endometrial cancer is the most common gynecologic malignancy in the United States. Funding for endometrial cancer has traditionally lagged behind that for other gynecological tumors, such as cervical cancer and ovarian cancer. Consequently, in the past there has been a lack of a coordinated basic and translational research effort devoted to endometrial cancer. In 2003, a group of basic scientists and physician- scientists from M.D. Anderson Cancer Center applied for and received NCI funding for an Endometrial Cancer SPORE. This group of investigators currently represents the only concentrated group of federally funded endometrial cancer researchers in the United States. For innovative, translational research in endometrial cancer to move forward, it will be necessary to bring together clinical investigators and laboratory scientists from a variety of different institutions across the country. Therefore, we propose to organize an annual Uterine Cancer Symposium with the following goals: 1) provide a meaningful forum to discuss cutting-edge developments in endometrial cancer biology; 2) attract experts in related fields (such as breast cancer and endocrinology) to encourage multi-disciplinary interactions; 3) promote collaborations between basic scientists and clinical investigators for the development of more innovative, high-impact translational research in endometrial cancer; and 4) encourage young, talented post-doctoral fellows, clinical residents/fellows, and faculty at the assistant professor level to enter the field of endometrial cancer research. The proposed Endometrial Cancer Symposium will be held on an annual basis in Houston, Texas. We successfully organized the 1st Uterine Cancer Biology Symposium in Houston in 2002, and we have a program of confirmed speakers for the 2nd Symposium to be held September 27 and 28, 2004. Topics for the annual Uterine Cancer Symposium series include hormonal mechanisms in endometrial cancer, molecular differences between aggressive (Type 2) and non-aggressive (Type 1) endometrial cancer, epidemiology of endometrial cancer, chemoprevention in high risk cohorts, endometrial hyperplasia/biomarkers of risk, mouse and cell culture models of endometrial cancer, and genetic events important in normal uterine development. For each symposium, a mixture of clinical topics and basic science topics will be presented to )romote the development of quality translational research.